红细胞改造作为药物载体研究进展  

Advances in Reformed Erythrocytes as Drug Deliver System

作　　者：陈超[1] 冯灵子 李佳[1] 鲍鸿一 夏栋林[1] 

机构地区：[1]南通大学公共卫生学院,江苏 南通

出　　处：《纳米技术》2021年第3期36-42,共7页Hans Journal of Nanotechnology

摘　　要：红细胞作为人体循环系统内数目最多的细胞,具有生物安全性高、免疫源性低、柔韧性强、系统循环长、药物负载量高等特点,可解决当前传统药物输送体系面临的许多挑战性问题,故而被广泛研究。目前红细胞修饰作为药物递送载体已形成了多种成熟、可行的方法,主要可分为:基因修饰的红细胞载体、非基因修饰的红细胞载体和红细胞膜修饰纳米颗粒。本文综述了红细胞作为纳米药物载体的概况及研究进展,总结了红细胞改造的研究成果,并展望了红细胞药物递送系统的发展趋势。Erythrocytes, the most abundant celltype in the human body, are high bio-safety, hypoimmunogenic, flexibility, longcycling, and high drug loading. It was extensively studied as it can overcomemany challenges in current conventional drug delivery systems. Up to now, thereare many mature and feasible methods in reforming erythrocytes as drugcarriers, which are mainly divided into the gene modification of erythrocytes,non-gene modification of erythrocytes and erythrocyte membrane modification ofnano particles. This review focuses on the latest research progress on thereformed erythrocytes as drug nanocarriers. We also summarized the primaryfindings of reformed erythrocytes and outlooked future developing trends inreformed erythrocytes drug delivery system.

关 键 词：药物递送体系 红细胞 纳米颗粒 细胞膜修饰 

分 类 号：R73[医药卫生—肿瘤]